When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs – Bloomberg

When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs
Bloomberg
When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs. With a flagship treatment that helps fewer than 11,000 people, how is Alexion making so much money? by. Benjamin Elgin. More stories by Benjamin Elgin. ,. Doni Bloomfield.